Zobrazeno 1 - 10
of 84
pro vyhledávání: ''
Autor:
Ashima Makol, Steven R. Ytterberg, Caitrin M. Coffey, Michael D. Richter, Cynthia S. Crowson, Matthew J. Koster, Kenneth J. Warrington
Publikováno v:
The Journal of Rheumatology. 47:518-523
Objective.To characterize the indication, outcomes, and adverse effects of rituximab (RTX) treatment in a large single-center cohort of patients with systemic rheumatoid vasculitis (RV).Methods.We retrospectively reviewed the medical charts of 17 pat
Autor:
William F. C. Rigby, William Reiss, Margaret Michalska, Darcy Gill, Jinglan Pei, Joel M. Kremer, Charles Peterfy, Christine Birchwood, Nora G. Singer
Publikováno v:
The Journal of Rheumatology. 47:325-332
Objective.To assess differences in joint damage and inflammation using magnetic resonance imaging (MRI) between patients with rheumatoid arthritis (RA) who achieved low disease activity with tocilizumab (TCZ) + methotrexate (MTX) and subsequently con
Publikováno v:
The Journal of Rheumatology. 47:255-263
Objective.Although prednisolone (PSL) and immunosuppressants are key drugs for Takayasu arteritis (TA) treatment, there is limited evidence on the optimal PSL dose. The aim of this study was to investigate the correlation between the initial PSL dose
Autor:
Toshio Kimura, Hubert van Hoogstraten, Sophie Guillonneau, Laure Gossec, Chieh-I Chen, E.K. Mangan, Clare Proudfoot, M. Reaney, Vibeke Strand
Publikováno v:
Journal of Rheumatology
Journal of Rheumatology, Journal of Rheumatology Publishing Company Limited, 2019, 46 (10), pp.1259-1267. ⟨10.3899/jrheum.180904⟩
Journal of Rheumatology, Journal of Rheumatology Publishing Company Limited, 2019, 46 (10), pp.1259-1267. ⟨10.3899/jrheum.180904⟩
Objective.We evaluated the effect of sarilumab on patient-perceived impact of rheumatoid arthritis (RA) using the 7-domain RA Impact of Disease (RAID) scale.Methods.Two phase III, randomized, controlled trials of sarilumab in patients with active, lo
Autor:
Gerd Horneff, Antigoni Siamopoulou-Mavridou, Hans-Iko Huppertz, Fabrizio De Benedetti, Rayfel Schneider, Alan Martin, Kirsten Minden, Nicolino Ruperto, Hermine I. Brunner, Clovis Arthur Silva, Ekaterina Alexeeva, Isabelle Koné-Paut, Benjamin Porter-Brown, Manuela Pardeo, Lawrence S. Zemel, Karen Onel, Jianmei Wang, Kamal N. Bharucha, Vyacheslav Chasnyk
Publikováno v:
The Journal of Rheumatology. 46:1117-1126
Objective.To determine whether neutropenia is associated with increased risk for infection in patients with systemic juvenile idiopathic arthritis (sJIA) and polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ).Me
Autor:
Daniela Graham, Dafna D. Gladman, Arthur Kavanaugh, Désirée van der Heijde, Lara Fallon, Cunshan Wang, Oliver FitzGerald
Publikováno v:
Journal of Rheumatology, 46(9), 1089-1096
Objective.To evaluate the effect of baseline risk factors on radiographic progression in patients with active psoriatic arthritis (PsA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and were
Autor:
Alejandro Alvarellos, Eduardo Ferreira Borba, Daniel Wojdyla, María H Esteva-Spinetti, Graciela S. Alarcón, Bernardo A. Pons-Estel, Lilian Tereza Lavras Costallat, José A. Gómez-Puerta, Verónica Saurit, Gil Reyes-Llerena, Mario H. Cardiel, Antonio Iglesias-Gamarra, Mary Carmen Amigo, Manuel F. Ugarte-Gil, Rosana Quintana, Eduardo Acevedo-Vásquez, Oscar Neira, E I Sato, Guillermo J. Pons-Estel, Nilzio Antônio da Silva, Luis J. Catoggio
Publikováno v:
The Journal of Rheumatology. 46:1299-1308
Objective.To determine the predictors of remission and low disease activity state (LDAS) in patients with systemic lupus erythematosus (SLE).Methods.Three disease activity states were defined: Remission = SLE Disease Activity Index (SLEDAI) = 0 and p
Autor:
K. Hambardzumyan, Ronald F van Vollenhoven, Johan K. Wallman, Rebecca Bolce, Saedis Saevarsdottir
Publikováno v:
Journal of rheumatology, 46(6), 555-563. Journal of Rheumatology
Objective.To investigate baseline levels of 12 serum biomarkers that constitute a multibiomarker disease activity test, as predictors of response to methotrexate (MTX) in patients with early rheumatoid arthritis (eRA).Methods.In 298 patients from the
Autor:
Francesco Muratore, Karthik Yeruva, Kenneth J. Warrington, Matthew J. Koster, Cristian Labarca, Cynthia S. Crowson
Publikováno v:
The Journal of Rheumatology. 46:501-508
Objective.To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA).Methods.Patients diagnosed with GCA from 1998 to 2013 with confirmed
Autor:
Naoki Inui, Hironao Hozumi, Tsuneyo Mimori, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yuzo Suzuki, Masato Kono, Yutaro Nakamura, Takafumi Suda, Hideki Yasui, Ran Nakashima
Publikováno v:
The Journal of Rheumatology. 46:509-517
Objective.The optimal treatment strategy for anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) is yet to be established. We aimed to evaluate the efficacy of gluc